Zhejiang Shengda Bio-Pharm Co., Ltd. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was CNY 362.01 million compared to CNY 349.52 million a year ago. Revenue was CNY 363.03 million compared to CNY 350.44 million a year ago.

Net loss was CNY 6.33 million compared to net income of CNY 39.93 million a year ago. Basic loss per share from continuing operations was CNY 0.04 compared to basic earnings per share from continuing operations of CNY 0.23 a year ago. Diluted loss per share from continuing operations was CNY 0.04 compared to diluted earnings per share from continuing operations of CNY 0.23 a year ago.